CL2017000682A1 - Compuestos novedosos de imidazopiridazina y su uso. - Google Patents

Compuestos novedosos de imidazopiridazina y su uso.

Info

Publication number
CL2017000682A1
CL2017000682A1 CL2017000682A CL2017000682A CL2017000682A1 CL 2017000682 A1 CL2017000682 A1 CL 2017000682A1 CL 2017000682 A CL2017000682 A CL 2017000682A CL 2017000682 A CL2017000682 A CL 2017000682A CL 2017000682 A1 CL2017000682 A1 CL 2017000682A1
Authority
CL
Chile
Prior art keywords
disease
compounds
imidazopyridazine compounds
novel
novel imidazopyridazine
Prior art date
Application number
CL2017000682A
Other languages
English (en)
Inventor
Wei-Guo Su
Guangxiu Dai
Weihan Zhang
Wei Deng
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CL2017000682A1 publication Critical patent/CL2017000682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

<p>LA PRESENTE MEMORIA DESCRIPTIVA PROPORCIONA COMPUESTOS NOVEDOSOS DE IMIDAZOPIRIDAZINA DE LA FÓRMULA I) Y SALES DE LOS MISMOS ACEPTABLES FARMACÉUTICAMENTE, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, UN PROCESO PARA SU PREPARACIÓN Y SUS EFECTOS PRÁCTICOS EN LA INHIBICIÓN DE PI3K Y SU USO POTENCIAL EN EL TRATAMIENTO DE UNA ENFERMEDAD QUE RESPONDE A LA INHIBICIÓN DE PI3K, POR EJEMPLO, UNA ENFERMEDAD INFLAMATORIA, UNA ENFERMEDAD AUTOINMUNITARIA O CÁNCER.</p>
CL2017000682A 2014-09-24 2017-03-22 Compuestos novedosos de imidazopiridazina y su uso. CL2017000682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410494483.5A CN105503877A (zh) 2014-09-24 2014-09-24 咪唑并哒嗪类化合物及其用途

Publications (1)

Publication Number Publication Date
CL2017000682A1 true CL2017000682A1 (es) 2017-10-30

Family

ID=55580324

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000682A CL2017000682A1 (es) 2014-09-24 2017-03-22 Compuestos novedosos de imidazopiridazina y su uso.

Country Status (32)

Country Link
US (2) US10208066B2 (es)
EP (1) EP3197898B1 (es)
JP (1) JP6381792B2 (es)
KR (2) KR102111570B1 (es)
CN (2) CN105503877A (es)
AR (1) AR101964A1 (es)
AU (1) AU2015320142B2 (es)
BR (1) BR112017006002B1 (es)
CA (1) CA2958671C (es)
CL (1) CL2017000682A1 (es)
CY (1) CY1122763T1 (es)
DK (1) DK3197898T3 (es)
EA (1) EA032643B1 (es)
ES (1) ES2765510T3 (es)
HR (1) HRP20192279T1 (es)
HU (1) HUE047377T2 (es)
IL (1) IL250703B (es)
LT (1) LT3197898T (es)
MX (1) MX2017003902A (es)
MY (1) MY178136A (es)
NZ (1) NZ729886A (es)
PE (1) PE20170936A1 (es)
PH (1) PH12017500564B1 (es)
PL (1) PL3197898T3 (es)
PT (1) PT3197898T (es)
RS (1) RS59831B1 (es)
SG (1) SG11201701545YA (es)
SI (1) SI3197898T1 (es)
TW (1) TWI707855B (es)
UA (1) UA118066C2 (es)
WO (1) WO2016045591A1 (es)
ZA (1) ZA201701312B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途
CN109516973A (zh) * 2017-09-19 2019-03-26 南京圣和药业股份有限公司 取代嘧啶类化合物、其制备方法及用途
CN110386937A (zh) * 2018-04-20 2019-10-29 和记黄埔医药（上海）有限公司 化合物的晶型和无定型
AR117461A1 (es) 2018-12-20 2021-08-04 Bayer Ag Compuestos de heterociclil piridazina como fungicidas
CN110028502B (zh) * 2019-05-29 2020-02-14 济南周行医药科技有限公司 一种激酶抑制剂类药物中间体的制备方法
US20240016152A1 (en) 2020-06-18 2024-01-18 Bayer Aktiengesellschaft Active compound combinations
CN114031558A (zh) * 2021-12-14 2022-02-11 无锡捷化医药科技有限公司 一种1-(6-氯哒嗪-4-基）乙基-1-酮的制备方法
WO2023143496A1 (zh) * 2022-01-28 2023-08-03 和记黄埔医药（上海）有限公司 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773958A (en) 1997-01-03 1998-06-30 Ovonic Battery Company, Inc. Apparatus for detecting cell reversal in rechargeable batteries
KR100389192B1 (ko) 1997-04-25 2003-06-27 다케다 야쿠힌 고교 가부시키가이샤 축합 피리다진 유도체, 그것의 제조 방법 및 용도
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
US8097617B2 (en) 2006-03-31 2012-01-17 Novartis Ag Organic compounds
MX2009004623A (es) 2006-10-30 2009-05-15 Novartis Ag Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
CN101528748A (zh) * 2006-10-30 2009-09-09 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的咪唑并哒嗪类化合物
AU2008250328A1 (en) 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
WO2012116237A2 (en) * 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US20140235643A1 (en) * 2011-10-04 2014-08-21 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013090725A1 (en) 2011-12-15 2013-06-20 Philadelphia Health & Education Corporation NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
ES2685568T3 (es) 2012-12-21 2018-10-10 Gilead Calistoga Llc Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药（上海）有限公司 咪唑并哒嗪类化合物及其用途

Also Published As

Publication number Publication date
MX2017003902A (es) 2017-12-07
AU2015320142A1 (en) 2017-04-27
TWI707855B (zh) 2020-10-21
PT3197898T (pt) 2020-01-17
US20170253618A1 (en) 2017-09-07
CA2958671A1 (en) 2016-03-31
AU2015320142B2 (en) 2018-02-15
KR102006670B1 (ko) 2019-10-01
WO2016045591A1 (en) 2016-03-31
EP3197898A4 (en) 2018-03-14
CN106715432B (zh) 2019-03-26
IL250703A0 (en) 2017-04-30
PE20170936A1 (es) 2017-07-13
KR102111570B1 (ko) 2020-05-18
CY1122763T1 (el) 2021-03-12
KR20170048598A (ko) 2017-05-08
IL250703B (en) 2020-09-30
CN105503877A (zh) 2016-04-20
RS59831B1 (sr) 2020-02-28
NZ729886A (en) 2020-06-26
TW201612181A (en) 2016-04-01
HRP20192279T1 (hr) 2020-03-06
JP6381792B2 (ja) 2018-08-29
US10611777B2 (en) 2020-04-07
JP2017528500A (ja) 2017-09-28
KR20190090065A (ko) 2019-07-31
PH12017500564A1 (en) 2017-08-30
EP3197898A1 (en) 2017-08-02
EA032643B1 (ru) 2019-06-28
AR101964A1 (es) 2017-01-25
UA118066C2 (uk) 2018-11-12
MY178136A (en) 2020-10-05
US10208066B2 (en) 2019-02-19
PL3197898T3 (pl) 2020-06-29
BR112017006002B1 (pt) 2023-02-14
SG11201701545YA (en) 2017-04-27
EP3197898B1 (en) 2019-11-27
SI3197898T1 (sl) 2020-03-31
PH12017500564B1 (en) 2017-08-30
BR112017006002A2 (pt) 2017-12-19
LT3197898T (lt) 2020-02-10
HUE047377T2 (hu) 2020-04-28
ZA201701312B (en) 2019-06-26
CA2958671C (en) 2019-04-30
ES2765510T3 (es) 2020-06-09
DK3197898T3 (da) 2020-01-20
CN106715432A (zh) 2017-05-24
US20190127391A1 (en) 2019-05-02
EA201790276A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
DOP2015000274A (es) Compuestos químicos
GT201600123A (es) Inhibidores de syk
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
NI201500096A (es) Compuesto químicos
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
NI201800071A (es) Compuestos de isoindol
ECSP17069696A (es) Compuestos novedosos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso